1952 Stock Overview
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$36.30|
|52 Week High||HK$104.80|
|52 Week Low||HK$30.00|
|1 Month Change||-10.37%|
|3 Month Change||-18.06%|
|1 Year Change||-58.75%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-50.10%|
Recent News & Updates
A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
How far off is Everest Medicines Limited ( HKG:1952 ) from its intrinsic value? Using the most recent financial data...
|1952||HK Biotechs||HK Market|
Return vs Industry: 1952 underperformed the Hong Kong Biotechs industry which returned -32.6% over the past year.
Return vs Market: 1952 underperformed the Hong Kong Market which returned -11.9% over the past year.
|1952 Average Weekly Movement||10.5%|
|Biotechs Industry Average Movement||9.3%|
|Market Average Movement||6.7%|
|10% most volatile stocks in HK Market||13.1%|
|10% least volatile stocks in HK Market||3.0%|
Stable Share Price: 1952 is more volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: 1952's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.
About the Company
|2017||227||Kerry Levan Blanchard||https://www.everestmedicines.com|
Everest Medicines Limited, a clinical-stage biopharmaceutical company, focuses on licensing, developing, and commercializing therapies for addressing critical unmet medical needs in Greater China and other Asia Pacific markets. It has a portfolio of eight clinical-stage drug candidates for the treatment of oncology, immunology, cardio-renal disease, and infectious diseases. Everest Medicines Limited was founded in 2017 and is headquartered in Shanghai, China.
Everest Medicines Fundamentals Summary
|1952 fundamental statistics|
Is 1952 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1952 income statement (TTM)|
|Cost of Revenue||CN¥0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-18.26|
|Net Profit Margin||0.00%|
How did 1952 perform over the long term?See historical performance and comparison
Is Everest Medicines undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1952 (HK$36.3) is trading below our estimate of fair value (HK$156.16)
Significantly Below Fair Value: 1952 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1952 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 1952 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1952's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1952 is good value based on its PB Ratio (1.2x) compared to the HK Biotechs industry average (3.1x).
How is Everest Medicines forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1952 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1952 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1952 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1952's revenue (46.5% per year) is forecast to grow faster than the Hong Kong market (11.7% per year).
High Growth Revenue: 1952's revenue (46.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1952 is forecast to be unprofitable in 3 years.
How has Everest Medicines performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: 1952 is currently unprofitable.
Growing Profit Margin: 1952 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 1952's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 1952's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1952 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54%).
Return on Equity
High ROE: 1952 has a negative Return on Equity (-76.25%), as it is currently unprofitable.
How is Everest Medicines's financial position?
Financial Position Analysis
Short Term Liabilities: 1952's short term assets (CN¥4.0B) exceed its short term liabilities (CN¥132.5M).
Long Term Liabilities: 1952's short term assets (CN¥4.0B) exceed its long term liabilities (CN¥434.9M).
Debt to Equity History and Analysis
Debt Level: 1952 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 1952's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1952 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1952 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Everest Medicines's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1952's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1952's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1952's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1952's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1952's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kerry Levan Blanchard (65 yo)
Dr. Kerry Levan Blanchard, Ph D., M.D., is an Executive Director at Everest Medicines Limited since February 25, 2020 and serves as its Chief Executive Officer since February 2020. Dr. Blanchard is also a...
Experienced Management: 1952's management team is considered experienced (2.4 years average tenure).
Experienced Board: 1952's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Everest Medicines Limited's employee growth, exchange listings and data sources
- Name: Everest Medicines Limited
- Ticker: 1952
- Exchange: SEHK
- Founded: 2017
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: HK$10.771b
- Shares outstanding: 296.72m
- Website: https://www.everestmedicines.com
Number of Employees
- Everest Medicines Limited
- Plaza 66
- Tower 1, Units 6601-6606
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/16 10:04|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.